Lipocine Inc.
Lipocine Inc. is a U.S.-based biopharmaceutical company developing oral drug-delivery products built on a proprietary lipid-based technology platform. Its programs target hard-to-deliver molecules across testosterone replacement, CNS disorders, liver disease, and women’s health, with TLANDO as its approved commercial product and the rest of the pipeline still in development.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved oral testosterone replacement therapy marketed through license partners.
Oral neuroactive steroid candidates for postpartum depression, MDD, and epilepsy.
Programs aimed at decompensated cirrhosis and prevention of overt hepatic encephalopathy.
Development assets focused on postpartum depression and pre-term birth.
Upfront, milestone, royalty, and research-support income from partners.
Products
Reported · share of revenue- License75.9 %
- Royalty24.1 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Lipocine sells primarily through licensing and commercialization partners rather than direct hospital or retail channels. Its end customers are patients and prescribing physicians in testosterone replacement, psychiatry, neurology, hepatology, and women’s health, while its direct counterparties are partners that pay license, milestone, royalty, and distribution fees. The company also relies on CROs and contract manufacturers to execute development and supply activities.
Verity, SPC, Pharmalink, and Aché commercialize TLANDO in their territories and pay milestones/royalties.
Endocrinology, urology, psychiatry, neurology, and hepatology prescribers choose oral options for patients.
Men and women seeking oral therapies that may improve convenience, adherence, and tolerability.
Potential collaborators for LPCN 1148, LPCN 2401, LPCN 1107, LPCN 1154, LPCN 2201, and LPCN 2101.
CROs and contract manufacturers that support clinical trials and drug production.
Strategy
Lipocine’s strategy is to use its oral drug-delivery platform to create differentiated products for large unmet medical needs, then advance them through partnerships and licensing. Near term, it is focused on supporting TLANDO commercialization, protecting IP, and progressing key pipeline assets such as LPCN 1154, while preserving liquidity through external financing and collaboration income.
Royalty and milestone income depends on partner execution and market uptake.
These programs could create future value if clinical data and regulatory progress are positive.
Partnerships reduce funding burden and broaden development reach.
Patent protection and lean overhead are critical for a small development-stage biotech.
Geography
Lipocine is headquartered and primarily operated from Salt Lake City, Utah, with most employees based there. Commercial exposure is global through out-licensing, but current revenue is concentrated in partner territories rather than direct product sales, and the company states it does not expect product sales until approvals outside the U.S. and Canada or FDA approval of additional candidates. Geography matters mainly through regulatory approvals, partner execution, and the ability to expand TLANDO beyond existing licensed territories.
Risks
Lipocine remains a development-stage biotech with heavy dependence on clinical outcomes, FDA review, and partner commercialization of TLANDO. It also faces financing risk because future trials, regulatory work, and commercialization support may require additional capital before meaningful product revenue is established.
- Clinical development failureImpact: HighLikelihood: Medium
Pipeline assets are early stage and depend on positive trial results to support NDA filings and approvals.
Exposure - Regulatory approval riskImpact: HighLikelihood: Medium
The company may not receive FDA approval or approval outside the U.S. for product candidates.
Exposure: All pipeline programs and future geographic expansion
- Partner commercialization riskImpact: HighLikelihood: Medium
TLANDO revenue depends on third-party licensees successfully marketing and distributing the product.
Exposure - Financing riskImpact: HighLikelihood: Medium
The company expects to need additional capital through equity, debt, or partnering.
Exposure: Operating runway and clinical development budget
- Third-party dependenceImpact: MediumLikelihood: Medium
CROs and contract manufacturers perform substantial trial and manufacturing work.
Exposure
Accounting
Judgemental itemsLicense fees and milestones are recognized based on contract terms and progress, which can shift revenue between periods.
Impact: Affects reported revenue timing and comparability
Royalties depend on partner sales performance and are inherently variable.
Impact: Creates quarter-to-quarter revenue volatility
Clinical study costs, CRO invoices, and outsourced manufacturing require accrual estimates.
Impact: Can change operating loss and cash burn
The Salt Lake City facility lease is a material operating commitment for a small company.
Impact: Affects operating expense and balance sheet liabilities
Similar listed companies
Publicly listed companies with a comparable business focus.
LB Pharmaceuticals Inc
LBRX · Pharmaceutical Preparations
Aptose Biosciences Inc.
APTOF · Biological Products, (No Diagnostic Substances)
BioVie Inc
BIVIW · Pharmaceutical Preparations
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Tectonic Therapeutic, Inc.
TECX · Biological Products, (No Diagnostic Substances)
Filana Therapeutics, Inc
FLNA · Pharmaceutical Preparations
Last updated: 24/09/2026